Reacción a "Reactions to clinical trial testing efficacy of new treatment for vitiligo"

The TRuE-V1 and V2 study is a well-designed study with a good number of patients studying the efficacy of a group of drugs called JAK pathway inhibitors in vitiligo. These drugs selectively block the action of the defenses that destroy melanocytes in the skin with the consequent loss of skin color. The novelty of this treatment compared to previous treatments lies in the selectivity of the JAK pathway inhibitors, since the former also aim to block the action of the defenses against melanocytes, but in a less selective manner. I think it is an interesting and positive study in that it is a first step that opens the door to research into new drugs in the future that act in a similar way. However, unless it is marketed at a reasonable price, I think it is difficult for the product under study to be of widespread application in patients with vitiligo, as there is not much difference in efficacy with some of the treatments we already have available and the cost is likely to be significantly higher. However, its good safety profile and ease of treatment are positive aspects to consider. 

Translated with www.DeepL.com/Translator (free version)